Abstract
A total of 30 patients (ten female/20 male), 9 years to 22 years old (mean age 17.3 years) and 30 healthy teenage controls (mean age 16.4 years) were included in our study. The patients had steroid-sensitive idiopathic nephrotic syndrome (INS) and had completed steroid therapy 4 years to 15 years ago. Height and weight, body mass index (BMI), body composition, and intima-media thickness (IMT) were determined, as were levels of total cholesterol (TCh), low-density lipoprotein cholesterol (LDL-Ch), high-density lipoprotein cholesterol (HDL-Ch), triacylglycerols (TAGs), homocysteine (HCY), and high-sensitivity C-reactive protein (hsCRP). We did not observe any differences between the study and control groups in IMT (0.47 ± 0.1 vs 0.46 ± 0.1 mm) and body composition (fat tissue and water content). Differences in HDL-Ch and hsCRP levels between groups were not significant. In the study group we found significantly higher TCh levels (187.6 ± 57.2 mg/dl vs 158.8 ± 25.7 mg/dl; P = 0.012), LDL-Ch (115.9 ± 63.7 mg/dl vs 79.4 ± 25.4 mg/dl; P = 0.005), HCY (12.3 ± 7.7 µmol/l vs 7.6 ± 1.6 µmol/dl; P < 0.001), apolipoprotein B (ApoB) (113.6 ± 30.0 mg/dl vs 78.7 ± 13.6 mg/dl; P < 0.001) and ApoA1 (203.5 ± 50.8 mg/dl vs 156.5 ± 12.4 mg/dl; P < 0.001) levels. Multi-factor analysis of the influence of independent factors (number of recurrences, duration of remission, age, gender, and BMI) on the parameters under investigation indicated a positive correlation between IMT and the number of recurrences. Conclusions: 1. Patients treated for idiopathic nephrotic syndrome in the past should undergo regular laboratory tests of atherosclerosis risk factors, including not only cholesterol and its fractions, but also ApoA1, ApoB and HCY. 2. It is necessary to continue systematic check-ups of the intima-media thickness of the carotid arteries among young patients with anamnesis of INS, especially among patients who suffered from numerous relapses of this disease.
Similar content being viewed by others
References
Orth SR, Ritz E (1998) The nephrotic syndrome. N Engl J Med 17:1202–1211
Thabet MA, Salcedo JR, Chan JC (1993) Hyperlipidemia in childhood nephrotic syndrome. Pediatr Nephrol 7:559–566
Radhakrishnan J, Appel AS, Valeri A, Appel GB (1993) The nephrotic syndrome, lipids and risk factors for cardiovascular disease. Am J Kidney Dis 22:135–142
Mérouani A, Lévy E, Mongeau JG, Robitaille P, Lambert M, Delvin EE (2003) Hyperlipidemic profiles during remission in childhood idiopathic nephrotic syndrome. Clin Biochem 36:571–574
Dogra GK, Herrmann S, Irish AB, Thomas MA, Watts GF (2002) Insulin resistance, dyslipidaemia, inflammation and endothelial function in nephrotic syndrome. Nephrol Dial Transplant 17:2220–2225
Kuo K, Still R, Cale S, McDowell I (1997) Standardization (external and internal) of HPLC assay for plasma homocysteine. Clin Chem 43:1653–1655
Minniti G, Piana A, Armani U, Cerone R (1998) Determination of plasma and serum homocysteine by high-performance liquid chromatography with fluorescence detection. J Chromatogr A 828:401–405
Ruth EM, Kemper MJ, Leumann EP, Laube GF, Neuhaus TJ (2005) Children with steroid-sensitive nephrotic syndrome come of age: long-term outcome. J Pediatr 147:202–207
Lewis MA, Baildom EM, Davis N, Houston IB, Postlethwaite RJ (1989) Nephrotic syndrome: from toddlers to twenties. Lancet 1:255–259
Foster BJ, Shults J, Zemel BS, Leonard MB (2004) Interactions between growth and body composition in children treated with high-dose chronic glucocorticoids. Am J Clin Nutr 80:1334–1341
Fakhouri F, Bocquet N, Taupin P, Presne C, Gagnadoux MF, Landais P, Lesavre P, Chauveau D, Knebelmann B, Broyer M, Grünfeld JP, Niaudet P (2003) Steroid-sensitive nephrotic syndrome: from childhood to adulthood. Am J Kidney Dis 41:550–557
Adhikari M, Manikkam NE, Coovadia HM (1992) Effects of repeated courses of daily steroids and of persistent proteinuria on linear growth in children with nephrotic syndrome. Pediatr Nephrol 6:4–9
Hung YT, Yang LY (2006) Follow-up of linear growth of body height in children with nephrotic syndrome. J Microbiol Immunol Infect 39:422–425
Matsukura H, Inaba S, Shinozaki K, Yanagihara T, Hara M, Higuchi A, Takada T, Tanizawa T, Miyawaki T (2001) Influence of prolonged corticosteroid therapy on the outcome of steroid-responsive nephrotic syndrome. Am J Nephrol 21:362–367
Kitamura M (1992) Growth retardation in children with frequent relapsing nephrotic syndrome on steroid-improvement of height velocity after administration of immunosuppressive agent. Nippon Jinzo Gakkai Shi 34:117–124
Jabłońska J (2004) Distant effects of steroid therapy in the nephrotic syndrome of childhood. Ann Acad Med Stetin 50:17–27
Drozdz D, Sancewicz-Pach K, Wierzchowska-Słowiaczek E (2000) Value of bioelectrical impedance analysis in the assessment of body water in children with nephrotic syndrome: initial results. Pol Merkuriusz Lek 8:224–225
Książek J, Niemirska A, Lipka M, Grenda R (2006) Evaluation of arterial intima-media thickness (IMT) in children with idiopathic nephrotic syndrome - preliminary report. Przegl Lek 63 [Suppl 3]:205–207
Falaschi F, Ravelli A, Martignoni A, Migliavacca D, Sartori M, Pistorio A, Perani G, Martini A (2000) Nephrotic-range proteinuria, the major risk factor for early atherosclerosis in juvenile-onset systemic lupus erythematosus. Arthritis Rheum 43:1405–1409
Woo KS, Chook P, Yu CW, Sung RYT, Qiao M, Leung SSF, Lam CWK, Metreweli C, Celermajer DS (2004) Effects of diet and exercise on obesity-related vascular dysfunction in children. Circulation 109:1981–1986
Rodenburg J, Vissers MN, Wiegman A, van Trotsenburg ASP, van der Graaf A, de Groot E, Wijburg FA, Kastelein JJP, Hutten B (2007) Statin treatment in children with familial hypercholesterolemia: the younger, the better. Circulation 116:664–668
Zilleruelo G, Hsia SL, Freundlich M, Gorman HM, Strauss J (1984) Persistence of serum lipid abnormalities in children with idiopathic nephrotic syndrome. J Pediatr 104:61–64
Kuźma E, Roszkowska-Blaim M (2006) Lipids abnormalities in children with refractory nephrotic proteinuria. Przegl Lek 63 [Suppl 3]:201–204
Pritchard PR (2000) Measurement and clinical significance of lecithin: cholesterol acyltransferase. In: Rifai N, Warnick GR, Dominiczak MH (eds) Handbook of lipoprotein testing, 2nd edn. AACC Press, Washington
Wasilewska A, Zoch-Zwierz W, Tobolczyk J, Tenderenda E (2007) High-sensitivity C-reactive protein (hs-CRP) level in children with nephrotic syndrome. Pediatr Nephrol 22:403–408
Podda GM, Lussana F, Moroni G, Faioni EM, Lombardi R, Fontana G, Ponticelli C, Maioli C, Cattaneo M (2007) Abnormalities of homocysteine and B vitamins in the nephrotic syndrome. Thromb Res 120:647–652
Joven J, Arcelús R, Camps J, Ordóñez-Llanos J, Vilella E, González-Sastre F, Blanco-Vaca F (2000) Determinants of plasma homocyst(e)ine in patients with nephrotic syndrome. J Mol Med 78:147–154
Arnadottir M, Hultberg B, Berg AL (2001) Plasma total homocysteine concentration in nephrotic patients with idiopathic membranous nephropathy. Nephrol Dial Transplant 16:45–47
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kniażewska, M.H., Obuchowicz, A.K., Wielkoszyński, T. et al. Atherosclerosis risk factors in young patients formerly treated for idiopathic nephrotic syndrome. Pediatr Nephrol 24, 549–554 (2009). https://doi.org/10.1007/s00467-008-1029-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00467-008-1029-1